Apolipoprotein E Gene and Functional MRI (fMRI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01287819|
Recruitment Status : Unknown
Verified October 2012 by Chaur-Jong Hu, Taipei Medical University Shuang Ho Hospital.
Recruitment status was: Recruiting
First Posted : February 1, 2011
Last Update Posted : October 19, 2012
- Apolipoprotein E gene (ApoE) is the most important genetic factor for Alzheimer disease (AD) and an important genetic factor for outcome of brain injury situations.
- Function magnetic resonance imaging (fMRI) is a powerful tool for study of both brain regional functions and brain network.
- Study about genetic contribution on fMRI is an emerging concept, which will help on understanding about how the genetics affecting the brain function.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Observational Model:||Case Control|
|Official Title:||Polymorphisms of Apolipoprotein E Gene and the Presentation of Resting-state Functional MRI|
|Study Start Date :||May 2012|
|Estimated Primary Completion Date :||April 2013|
|Estimated Study Completion Date :||June 2013|
APOE4 (+) and APE4 (-)
APOE4 (+) 10 people APOE4 (-) 20 people from 200 participants
- amyloid load by amyloid-PET examination [ Time Frame: every 5 years ]The primary end point of this study is the quantity of amyloid load in brain. The amyloid load will be calculated based on the results of AV45 PET study. The comparison between mTBI and controls will be conducted by ANOVA test. The confounders include vascular risks for AD, such as hypertension, diabetes, and APOE genotypes, education.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01287819
|Contact: Chaur-Jong Hu, M.D.||886-2-22490088 ext email@example.com|
|New Taipei City, Taiwan, 235|
|Contact: Chaur-Jong Hu, M.D. 886-2-22490088 ext 8112 firstname.lastname@example.org|
|Principal Investigator: Chaur-Jong Hu, M.D.|
|Principal Investigator:||Chaur-Jong Hu, M.D.||Taipei Medical University Shuang Ho Hospital|